Frontage Holdings Corporation Provides Preliminary Consolidated Earnings Guidance for the Six Months Ended June 30, 2019
July 30, 2019 at 05:05 am EDT
Share
Frontage Holdings Corporation provided preliminary consolidated earnings guidance for the six months ended June 30, 2019. The group expected that the profit attributable to the owners of the company for the six months ended June 30, 2019 will be more than 300% of that for the six months ended June 30, 2018. Such increase in the profit of the Company was primarily attributable to: (i) a significant growth in revenue driven by an increased demand for services and implementing of the Group's "Two Countries, One System" strategy; and (ii) efficiency enhancement of the Group's business operation. The Company is still in the process of finalizing the interim results of the Group for the six months ended June 30, 2019.
Frontage Holdings Corporation is a holding company. The principal activities of the Company and its subsidiaries are to provide laboratory and related services to pharmaceutical and agrochemical companies. The Company is a contract research organization (CRO) providing integrated, science-driven, product development services throughout the drug discovery and development process to enable life science companies to achieve their drug development goals. Its segments include North America and the Peopleâs Republic of China (PRC). The North America segment includes laboratory testing, chemistry, manufacturing and control (CMC), preclinical research, early stage clinical/bioequivalence and chemistry services in the USA and Canada. PRC segments include laboratory testing, CMC, preclinical research, early stage clinical/ bioequivalence and chemistry services in the PRC. Its preclinical research services consist of drug metabolism and pharmacokinetic (DMPK) and safety and toxicology.
FRONTAGE HOLDINGS CORPORATION 
